Amendments to the Claims

The listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

- 1. (Original) A method of killing cancer cells, comprising administration to said cells of an effective amount of a c-FLIP inhibitor, wherein the c-FLIP inhibitor is administered as the sole cytotoxic agent in the substantial absence of other cytotoxic agents.
- (Original) A method of treating cancer comprising administration to a subject in need thereof a therapeutically effective amount of a c-FLIP inhibitor, wherein the c-FLIP inhibitor is administered as the sole cytotoxic agent in the substantial absence of other cytotoxic agents.
- 3. (Original) A method of killing cancer cells having a p53 mutation, comprising administration to said cells of:
 - (a) a c-FLIP inhibitor and
 - (b) a chemotherapeutic agent, wherein the chemotherapeutic agent is a thymidylate synthase inhibitor, a platinum cytotoxic agent or a topoisomerase inhibitor.
- 4. (Original) A method of treating cancer associated with a p53 mutation comprising administration to a subject in need thereof
 - (a) a c-FLIP inhibitor and
 - (b) a chemotherapeutic agent, wherein the chemotherapeutic agent is a thymidylate synthase inhibitor, a platinum cytotoxic agent or a topoisomerase inhibitor.

PHIP\518125\1 - 3 -

- 5. (Currently Amended) The method according to claim 3 or claim 4, further comprising administration of:
 - (c) a death receptor binding member.
- 6. (Original) The method according to claim 5, wherein the death receptor is FAS.
- 7. (Original) The method according to claim 6, wherein the binding member is the FAS antibody CH11.
- 8. (Currently Amended) The method according to any one of claims claim 3 to 7, wherein the chemotherapeutic agent is 5-FU, oxaliplatin or CPT-11.
- 9. (Original) The method according to claim 8, wherein the chemotherapeutic agent is 5-FU or oxaliplatin.
- 10. (Currently Amended) The method according to any one of claims 3 to 9 claim 4, wherein the c-FLIP inhibitor and the chemotherapeutic agent are administered in a potentiating ratio.
- 11. (Original) The method according to claim 10, wherein the c-FLIP inhibitor and the chemotherapeutic agent are administered in concentrations sufficient to produce a CI of less than 0.85.
- 12. (Currently Amended) The method according to any one of claims 3 to 11 claim 4, wherein the p53 mutation is such that p53 is completely inactivated in the cancer cells.
- 13. (Currently Amended) The method according to any one of claims 3 to 11 claim 4, wherein the p53 mutation is a missense mutation resulting in the substitution of histidine (R175H mutation) or a missense mutation resulting in the substitution of tryptophan (R248W mutation) for arginine.

- 4 -

PHIP\518125\1

- 14. (Currently Amended) The method according to any one of claims 1 to 13 claim 2, wherein said c-FLIP inhibitor is an RNAi agent, which modulates expression of a c-FLIP gene.
- 15. (Original) The method according to claim 14 wherein the c-FLIP inhibitor is an RNAi agent having nucleotide sequence

AAG CAG TCT GTT CAA GGA GCA (SEQ ID NO: 1) or AAG GAA CAG CTT GGC GCT CAA (SEQ ID NO: 2).

- 16. (Cancelled)
- 17. (Cancelled)
- 18. (Cancelled)
- 19. (Cancelled)
- 20. (Cancelled)
- 21. (Cancelled)
- 22. (Cancelled)
- 23. (Cancelled)
- 24. (Cancelled)
- 25. (Cancelled)
- 26. (Cancelled)
- 27. (Cancelled)
- 28. (Cancelled)
- 29. (Original) A pharmaceutical composition for the treatment of cancer, wherein the composition comprises a c-FLIP inhibitor as the sole cytotoxic agent and a pharmaceutically acceptable excipient, diluent or carrier, wherein the composition is for treatment in the absence of other cytotoxic agents.
- 30. (Original) A pharmaceutical composition for the treatment of a cancer associated with a p53 mutation, wherein the composition comprises
 - (a) a c-FLIP inhibitor

- (b) a chemotherapeutic agent, wherein the chemotherapeutic agent is a thymidylate synthase inhibitor, a platinum cytotoxic agent or a topoisomerase I inhibitor and
- (c) a pharmaceutically acceptable excipient, diluent or carrier.
- 31. (Currently Amended) The composition according to claim 30, further comprising (c) a death receptor binding member.
- 32. (Original) The composition according to claim 31, wherein the death receptor is FAS.
- 33. (Original) The composition according to claim 32, wherein the binding member is the FAS antibody CH11.
- 34. (Currently Amended) The composition according to any one of claims claim 30 to 33, wherein the chemotherapeutic agent is 5-FU, oxaliplatin or CPT-11.
- 35. (Original) The composition according to claim 34, wherein the chemotherapeutic agent is 5-FU or oxaliplatin.
- 36. (Currently Amended) The composition according to any one of claims claim 30 to 36, wherein the c-FLIP inhibitor and the chemotherapeutic agent are present in a potentiating ratio.
- 37. (Original) The composition according to claim 36, wherein the c-FLIP inhibitor and the chemotherapeutic agent are present in concentrations sufficient to produce a CI of less than 0.85.
- 38. (Currently Amended) The composition according to any one of claims claim 30 to 37, wherein the p53 mutation is such that p53 is completely inactivated in the cancer cells.

- 6 -

PHIP\518125\1

- 39. (Currently Amended) The composition according to any one of claims claim 30 to 37, wherein the p53 mutation is a missense mutation resulting in the substitution of histidine (R175H mutation) or a missense mutation resulting in the substitution of tryptophan (R248W mutation) for arginine.
- 40. (Currently Amended) The composition according to any one of claims claim 29 to 39, wherein said c-FLIP inhibitor is an RNAi agent, which modulates expression of a c-FLIP gene.
- 41. (Original) The composition according to claim 40 wherein the c-FLIP inhibitor is an RNAi agent having nucleotide sequence

 AAG CAG TCT GTT CAA GGA GCA (SEQ ID NO: 1) or

 AAG GAA CAG CTT GGC GCT CAA (SEQ ID NO: 2).
- 42. (Original) A kit for the treatment of cancer associated with a p53 mutation, said kit comprising
 - (a) a c-FLIP inhibitor and
 - (b) a chemotherapeutic agent, wherein the chemotherapeutic agent is a
 thymidylate synthase inhibitor, a platinum cytotoxic agent or a topoisomerase
 I inhibitor and
 - (c) instructions for the administration of (a) and (b) separately, sequentially or simultaneously.
- 43. (Original) An RNAi agent having nucleotide sequence
 AAG CAG TCT GTT CAA GGA GCA (SEQ ID NO: 1) or
 AAG GAA CAG CTT GGC GCT CAA (SEQ ID NO: 2).
- 44. (Original) An RNAi agent consisting of nucleotide sequence AAG CAG TCT GTT CAA GGA GCA (SEQ ID NO: 1) or AAG GAA CAG CTT GGC GCT CAA (SEQ ID NO: 2).

- 45. (New) The method according to claim 4, wherein said c-FLIP inhibitor is an RNAi agent, which modulates expression of a c-FLIP gene.
- 46. (New) The method according to claim 45, wherein the c-FLIP inhibitor is an RNAi agent having nucleotide sequence

AAG CAG TCT GTT CAA GGA GCA (SEQ ID NO: 1) or AAG GAA CAG CTT GGC GCT CAA (SEQ ID NO: 2).

- 47. (New) The composition according to claim 30, wherein said c-FLIP inhibitor is an RNAi agent, which modulates expression of a c-FLIP gene.
- 48. (New) The composition according to claim 47, wherein the c-FLIP inhibitor is an RNAi agent having nucleotide sequence

AAG CAG TCT GTT CAA GGA GCA (SEQ ID NO: 1) or AAG GAA CAG CTT GGC GCT CAA (SEQ ID NO: 2).